PHARM.AS : Summary for PHARMING GROUP - Yahoo Finance

U.S. Markets close in 4 hrs 37 mins

Pharming Group N.V. (PHARM.AS)

Amsterdam - Amsterdam Delayed Price. Currency in EUR
Add to watchlist
0.31+0.01 (+4.70%)
As of 5:04PM CEST. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close0.30
Bid0.19 x 500000
Ask0.19 x 2275000
Day's Range0.30 - 0.32
52 Week Range0.15 - 0.37
Avg. Volume4,781,466
Market Cap149.42M
PE Ratio (TTM)-7.43
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Pharming Group NV breached its 50 day moving average in a Bearish Manner : PHARM-NL : March 15, 2017
    Capital Cubelast month

    Pharming Group NV breached its 50 day moving average in a Bearish Manner : PHARM-NL : March 15, 2017

    Categories: Europe Stock Alerts Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Pharming Group NV. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • PR Newswire2 months ago

    Pharming Group Report on Preliminary Financial Results for 2016

    LEIDEN, Netherlands, March 9, 2017 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) presents its (unaudited) financial report for the full ...

  • PR Newswire3 months ago

    Pharming Announces Additional Conversions of its Amortizing Bonds

    Pharming Group N.V. ("Pharming" or "the Company") (PHARM.AS) today announced that it has issued a further 7,558,479 new shares (in addition to the 10,823,881 new shares announced in the press release dated 26 January 2017) to holders of the Amortizing Bonds due 2017/8 who have converted more of their Bonds into shares ahead of the due date for payment of the first and also the second instalment on those Bonds.  These conversions have been credited against the scheduled first and second instalments of the Bonds, due on 1 February 2017 and 1 March 2017, completely eliminating the first instalment cash payment and also almost completely settling the second instalment as well. The conversions all took place at the conversion price of the Amortizing Bonds of €0.289 per share, a premium of 30% to the 20-day volume-weighted average price of €0.222 as at 18 November 2016, the business day prior to publication of Pharming's Rights Issue prospectus on 21 November 2016 which included details of the Amortizing Bonds, and a premium of 41% to the rights price offered to existing shareholders in the rights issue on that date.  As result of these conversions, the total amount outstanding of the Amortizing Bonds has been reduced from €45.0 million to €39.7 million.